Every 8-K that Repare Therapeutics Inc. (RPTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RPTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPTX filings page.
Repare Therapeutics Inc. completed its previously announced acquisition by XenoTherapeutics’ wholly owned subsidiary, Xeno Acquisition Corp., resulting in a change of control and Repare becoming a wholly owned subsidiary. Shareholders received approximately US$2.20 in cash per common share, plus one non-transferable contingent value right (CVR) per share for potential future cash payments under a CVR agreement.
In connection with the closing, Repare requested that Nasdaq suspend trading of its common shares after January 28, 2026 and file Form 25 to delist and deregister the shares. The purchaser intends to file Form 15 to terminate registration and suspend Exchange Act reporting, and the company has applied to cease to be a reporting issuer in Québec. All Repare directors resigned at the effective time, and Jon Adkins, previously the sole director and officer of the purchaser, became the sole director and is expected to serve as the sole officer of Repare.
Repare Therapeutics Inc. reported the results of a Special Meeting of shareholders held on January 16, 2026. Shareholders approved a special resolution for a plan of arrangement under Québec corporate law, under which Xeno Acquisition Corp. will acquire all of the issued and outstanding common shares, subject to the terms described in the company’s proxy statement.
The arrangement resolution passed with strong support, receiving 25,954,251 votes for and 58,162 against, with 4,811 abstentions, representing 99.76% of votes cast. Excluding votes required to be excluded under Multilateral Instrument 61-101, 25,879,894 votes for and 58,162 against, with 4,811 abstentions, also equaled 99.76% of votes cast.
Shareholders also approved, on an advisory non-binding basis, the compensation related to the transaction, with 25,846,791 votes for and 166,117 against. As a contingency if the arrangement were not approved or is later terminated, shareholders passed resolutions authorizing a potential voluntary liquidation and dissolution of the company and the possible appointment of KPMG LLP or another nationally recognized liquidator.
Repare Therapeutics Inc. (RPTX) agreed to be acquired by non‑profit XenoTherapeutics, Inc. via a court‑approved plan of arrangement. Shareholders are expected to receive an estimated cash payment of about $1.82 per common share at closing, plus one non‑transferable contingent value right (CVR) per share that may pay additional cash based on future milestones under a CVR Agreement.
The company’s independent transaction committee and full board unanimously determined the arrangement is fair and in the best interests of shareholders and will recommend that shareholders vote in favor. The deal requires approval by at least 66⅔% of votes cast and a majority of minority shareholders, court approval under Québec law, and limits on dissenting shares, among other customary conditions. Officers and directors holding about 0.25% of outstanding shares have signed voting and support agreements in favor of the transaction.
Repare Therapeutics reported a Regulation FD update announcing that the abstract from its Phase 1 LIONS trial of RP-1664 has been made available. The preliminary data in the abstract will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The abstract, titled “Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification,” is posted on the Company’s website under Science > Scientific References.
The Company noted that information on its website is not incorporated by reference into other filings unless specifically stated.
Repare Therapeutics Inc. filed a current report to note that it issued a press release on August 8, 2025 detailing recent business highlights and its financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this report.
The company clarifies that the information in this report and the accompanying exhibits is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced, and that information on its website is not part of this disclosure.
Repare Therapeutics Inc. (Nasdaq: RPTX) filed a Form 8-K to disclose changes approved by its Compensation Committee on June 13, 2025 to the severance package of Michael Zinda, Ph.D., Executive Vice President & Chief Scientific Officer.
Under the amended terms, if Dr. Zinda is terminated without “cause” or resigns for “good reason,” and the separation is not in connection with a change-in-control, he will receive:
- Lump-sum cash equal to nine months of current base salary.
- COBRA premiums paid by Repare for up to 12 months post-separation.
- Accelerated vesting of all unvested equity awards for nine months from the separation date.
- Pro-rated target bonus for the year of separation, paid in a lump sum.
If a change in control occurs within 90 days after the separation date, Dr. Zinda will instead receive the enhanced change-in-control severance stipulated in Section 5.7(c) of his previously disclosed Employment Agreement. All other existing severance protections in that agreement remain unchanged.
The disclosure is limited to executive compensation; no financial results, operational updates, or strategic transactions were reported.